Oncology Archive

A building with a stone facade displays a sign that reads
An Open-Label Phase 1 Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of PRTH-101 Alone or in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)
A building with a stone facade displays a sign that reads
A Phase 1, First-in-Human Study of the SMARCA2 Degrader, PLX-61639, in Patients With SMARCA4-Mutated Locally Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
Natera/Yanuvia_SCORE_Moorthy
International team led by HonorHealth Research Institute and U of A develop 3D chip platform for laboratory testing in cancer research
Cody Patten
A female patient sits on an exam table and speaks with a male doctor in a white coat in a medical office.
HonorHealth Research Institute study proves safety of out-patient chemotherapy preparation for new melanoma cancer therapy
A doctor in a white coat gestures with both hands while speaking to a seated patient in a medical office with a window in the background.
New technique at HonorHealth Research Institute uses ultrasound to activate drugs targeting pancreatic cancer
A building with a stone facade displays a sign that reads
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors